<DOC>
	<DOC>NCT00374231</DOC>
	<brief_summary>To determine the safety and efficacy of early corticosteroid discontinuation in liver transplant recipients more than 90 days post transplant, utilizing a combination of two drugs (tacrolimus and mycophenolate mofetil) for maintenance immunosuppressant therapy.</brief_summary>
	<brief_title>Single Center Pilot Study of Corticosteroid Discontinuation in Liver Transplant Recipients</brief_title>
	<detailed_description>To determine the safety and efficacy of early corticosteroid discontinuation in liver transplant recipients more than 90 days post transplant, utilizing a combination of two drugs (tacrolimus and mycophenolate mofetil) for maintenance immunosuppression therapy.</detailed_description>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Greater than 90 days post transplant. Free from rejection within the last 30 days. Patient with primary diagnosis of AIH will be evaluated on an individual basis. Negative pregnancy test. Practicing an acceptable method of birth control. Capable of providing written informed consent. Rejection within the last 30 days. Patients with AIH unable to discontinue corticosteroids. Patients currently receiving systemic corticosteroids for other medical diseases in which the physician feels discontinuation is contraindicated. Known sensitivity or contraindication to tacrolimus or MMF. Kidney, pancreas, islet, heart, lung, or small bowel transplant recipient. Pregnant or lactating.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Liver</keyword>
	<keyword>Transplant</keyword>
	<keyword>Corticosteroid withdrawal</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>CellCept</keyword>
	<keyword>MMF</keyword>
	<keyword>Mycophenolate mofetil</keyword>
</DOC>